RIJSWIJK, Netherlands & BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, today announced an agreement with Centrient Pharmaceuticals (‘Centrient’), a global business-to-business pioneer in sustainable, biosynthetic pharmaceutical products, including antibiotics, next-generation statins, and anti-fungals,, to open its new dedicated innovation lab at Almirall’s R&D centre.

荷兰RIJSWIJK和西班牙巴塞罗那-（BUSINESS WIRE）-专注于医学皮肤病学的全球生物制药公司Almirall S.A.（BME:ALM）今天宣布与Centrient Pharmaceuticals（'Centrient'）达成协议，Centrient Pharmaceuticals是可持续生物合成药物产品（包括抗生素，新一代他汀类药物和抗真菌药物）的全球商业对商业先驱，，在Almirall的研发中心开设新的专门创新实验室。

Centrient's new Innovation Laboratory will start operations in the first quarter of 2024..

Centrient的新创新实验室将于2024年第一季度开始运营。。

This development builds upon Almirall’s commitment to transform its R&D center in Sant Feliu de Llobregat into a dynamic collaborative environment. The center serves as a hub where researchers from biotech companies, startups, universities, and other scientific institutions can collaborate fostering an ideal environment for innovation.

这一发展建立在Almirall致力于将Sant Feliu de Llobregat的研发中心转变为动态协作环境的基础上。该中心是生物技术公司，创业公司，大学和其他科学机构的研究人员可以合作培育理想创新环境的中心。

Through this partnership with Centrient, following an earlier agreement with ZeClinics earlier this year, Almirall reinforces its mission to create a platform where knowledge and science intersect..

通过与Centrient的合作关系，在今年早些时候与ZeClinics达成早期协议之后，Almirall加强了其创建知识和科学交叉平台的使命。。

The establishment of an Innovation Laboratory at Almirall's R&D facilities is a strategic milestone for Centrient. It positions Centrient to forge a more diversified and innovative portfolio, a pivotal element of the company's strategic roadmap leading into 2030. Moreover, Centrient seeks to leverage its manufacturing prowess and process development acumen, emerging as a crucial player within an open innovation paradigm.

在Almirall的研发设施建立创新实验室是中心的战略里程碑。它以Centrient为基础，组建更加多样化和创新的投资组合，这是公司到2030年战略路线图的关键要素。此外，Centrient试图利用其制造能力和过程开发敏锐度，成为开放式创新范式中的关键角色。

This transformation will accelerate Centrient's evolution from a manufacturer to an innovation partner in the markets it serves..

这种转变将加速Centrient从制造商发展到其服务市场的创新合作伙伴。。

Located in Barcelona, the laboratory will provide a central hub for Centrient’s product and process innovation, complementing and building on its existing research and development capabilities around the world. The laboratory's core focus areas encompass Centrient's biotechnology expertise, including strain conservation, strain and enzyme development, industrial microbiology, laboratory-scale fermentation, and enzyme processing and application..

该实验室位于巴塞罗那，将为中心产品和工艺创新提供中心枢纽，补充和建立全球现有的研究和开发能力。该实验室的核心重点领域包括Centrient的生物技术专业知识，包括菌株保存，菌株和酶开发，工业微生物学，实验室规模发酵以及酶加工和应用。。

Rex Clements, Chief Executive Officer of Centrient Pharmaceuticals, expressed his enthusiasm, stating: 'The new Innovation Laboratory is an exhilarating strategic leap for Centrient Pharmaceuticals. It will enable us to cement our position as a technology leader, generate enduring value for our stakeholders, and secure a more competitive market standing.

Centrient Pharmaceuticals首席执行官Rex Clements表示了他的热情，他说：“新的创新实验室是Centrient Pharmaceuticals令人振奋的战略飞跃。它将使我们能够巩固我们作为技术领导者的地位，为我们的利益相关者创造持久的价值，并确保更具竞争力的市场地位。

By building upon our existing capabilities in product and process innovation, we are poised to cultivate a broader and more diverse product portfolio rooted in innovative, sustainable manufacturing practices. Our aspiration is to continue driving positive transformation within the healthcare industry and society at large, expanding our impact to reach more patients worldwide.'.

通过建立我们现有的产品和工艺创新能力，我们准备培养更广泛，更多样化的产品组合，其根源在于创新，可持续的制造实践。我们的愿望是继续推动医疗行业和整个社会的积极转型，扩大我们的影响，以覆盖全球更多的患者。

Jorge Gil-Martinez, Chief Scientific Officer of Centrient Pharmaceuticals said: “This collaboration represents a huge step in our journey towards an Open Innovation model, where we aim to create synergies with strategic partners to accelerate our mission: enable State of the Art innovative processes for our products and a diversified portfolio.”.

Centrient Pharmaceuticals首席科学官豪尔赫·吉尔·马丁内斯（Jorge Gil Martinez）说：“这项合作是我们走向开放式创新模式之旅中的一大步，我们的目标是与战略合作伙伴建立协同效应，加快我们的使命：实现最先进的创新我们产品的流程和多元化的投资组合“。

Karl Ziegelbauer, Ph.D., Almirall's Chief Scientific Officer, added, 'This agreement to host Centrient’s innovation lab at our R&D center underscores Almirall's commitment to fostering a collaborative environment for cutting-edge innovation. At Almirall, we have always prioritized innovation, and this collaboration is another step forward in our mission to support research projects for biotech companies, start-ups, universities, and more..

Almirall首席科学官Karl Ziegelbauer博士补充说：“在我们的研发中心主办Centrient创新实验室的这项协议强调了Almirall致力于培养尖端创新的合作环境。在Almirall，我们一直优先考虑创新，这项合作是我们支持生物技术公司，初创企业，大学等研究项目的使命的又一步。。

Working together to catalyse open innovation

共同努力推动开放式创新

Sharing a creative scientific space will open up opportunities for open innovation between the companies as well as future partners. Working in close proximity will allow Centrient and Almirall colleagues to share knowledge and expertise as part of a tight-knit community of innovators.

共享创新的科学空间将为公司与未来合作伙伴之间的开放式创新开辟机会。密切合作将使Centrient和Almirall同事能够分享知识和专业知识，作为紧密联系的创新者社区的一部分。

Almirall's ultimate goal is to create a pharmaceutical innovation hub where different companies can execute their innovation strategies. This will create the ideal environment for innovation, with companies connecting the dots by complementing each other's capabilities and expertise.

Almirall的最终目标是创建一个制药创新中心，不同公司可以在其中执行其创新战略。这将为创新创造理想的环境，公司通过互补彼此的能力和专业知识来连接这些点。

About Almirall

阿尔米拉利

Almirall is a global biopharmaceutical company focused on medical dermatology. We collaborate with scientists and healthcare professionals to address patients' needs through science to improve their lives. Our Noble Purpose is at the core of our work: 'Transform the patients' world by helping them realize their hopes and dreams for a healthy life'.

Almirall是一家专注于医学皮肤病学的全球生物制药公司。我们与科学家和医疗保健专业人员合作，通过科学解决患者的需求，改善他们的生活。我们崇高的目标是我们工作的核心：“帮助患者实现健康生活的希望和梦想，改变患者的世界”。

We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need..

我们投资差异化和突破性的医用皮肤科产品，为有需要的患者带来创新的解决方案。。

The company, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has focused intensely on patients' needs. Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees.

该公司成立于1944年，总部设在巴塞罗那，在西班牙证券交易所（证券交易所：ALM）上市交易。在其79年的历史中，Almirall一直专注于患者的需求。Almirall在21个国家直接存在，70多个国家拥有战略协议，约有1800名员工。

Total revenue in 2022 was €878.5 MM..

2022年的总收入为878.5毫米。。

For more information, please visit almirall.com

欲了解更多信息，请访问almirall.com

About Centrient

关于中心

Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually..

Centrient Pharmaceuticals是可持续，酶促抗生素，下一代他汀类药物和抗真菌药物的全球商业对商业领导者。我们是一家制药公司，目标明确：通过创新和可持续的药品制造改善生活-每年拯救世界各地数百万人的生命。。

Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Our world-leading proprietary enzymatic technology PureActives® ensures an unmatched eco-friendly production process for our high-quality products. Driven by our Purpose and Sustainability through our ESG vision, we aim to create value for Centrient and our stakeholders.

关于我们的产品组合，我们生产和销售中间体和活性药物成分（API），以及成品剂型（FDF）。我们世界领先的专有酶技术PureActives®为我们的高品质产品确保了无与伦比的环保生产工艺。在我们的目标和可持续性的推动下，通过我们的ESG愿景，我们的目标是为中心和我们的利益相关者创造价值。

Centrient is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing..

Centrient是AMR行业联盟的董事会成员，长期倡导制造业的行业责任。。

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico.

我们公司成立于150年前的“Nederlandsche Gist-en Spiritusfabriek”，最近被称为Gist Brocades和DSM Sinochem Pharmaceuticals。我们总部设在荷兰鹿特丹，在中国，印度，荷兰，西班牙，美国和墨西哥设有生产设施和销售办事处。

Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm..

Centrient Pharmaceuticals由领先的全球私人投资公司贝恩资本私募股权拥有。。

For more information, please visit centrient.com/

欲了解更多信息，请访问centrient.com/

Legal warning

法律警告

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are 'forward-looking statements'. These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable.

本文档仅包含摘要信息，并非详尽无遗。本文件中包含的事实，数字和意见，除了历史之外，都是“前瞻性声明”。这些陈述是基于目前可用的信息以及公司认为合理的最佳估计和假设。

These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law..

这些陈述涉及公司无法控制的风险和不确定性。因此，实际结果可能与此类前瞻性声明所声明的结果大不相同。除非适用法律另有要求，否则本公司明确放弃修改或更新本文档中包含的任何前瞻性声明，目标或估计的义务，以反映此类前瞻性声明所基于的假设，事件或情况的任何变化。。